Advertisement

Topics

New data at EAN show Roche’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary progressive multiple sclerosis

01:00 EDT 23 Jun 2017 | Hoffmann-La Roche Ltd

Roche announced today that new post-hoc analyses from the OCREVUS™ (ocrelizumab) Phase III clinical trial programme in people with relapsing and primary progressive forms of multiple sclerosis (RMS and PPMS) will be presented at the 3rd Congress of the European Academy of Neurology (EAN) from 24 June to 27 June in Amsterdam, Netherlands.

Original Article: New data at EAN show Roche’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary progressive multiple sclerosis

NEXT ARTICLE

More From BioPortfolio on "New data at EAN show Roche’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary progressive multiple sclerosis"

Advertisement
Quick Search
Advertisement
Advertisement